Skip to main content
Top
Published in:

Open Access 01-12-2024 | Pneumonia | Case Report

Atypical presentation of PJP: hypercalcemia and kidney injury in an allogeneic stem cell transplant recipient

Authors: Yunus Can Özalp, Hajrij Shehabie, Mehmet Günhan Tekin, Süreyya Yiğit Kaya, Hüseyin Saffet Beköz, Senem Maral, Ömür Gökmen Sevindik, Leylagül Kaynar

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection that primarily affects immunocompromised individuals. Typical symptoms of PJP include the subacute onset of dyspnea, nonproductive cough, and low-grade fever. In hematology patients, particularly those who are allogeneic stem cell transplant recipients, the disease often presents with a more aggressive clinical course. While hypercalcemia has been documented as a manifestation of PJP in some solid organ transplant recipients, it has not been reported in hematology or stem cell transplant patients.

Case presentation

Here, we present a case of PJP in a 56-year-old male allogeneic stem cell transplant recipient, who developed hypercalcemia and renal failure during the late post-transplant period. The patient had a history of allogeneic stem cell transplantation due to acute myeloid leukemia. He presented with symptoms of fatigue and weakness. Laboratory tests revealed hypercalcemia (13.8 mg/dL) and elevated serum creatinine levels (2.3 mg/dL). The patient was hospitalized, and despite initial treatment with hydration and furosemide, the hypercalcemia persisted, leading to the administration of denosumab. During follow-up, hypoxia was detected, and a chest CT scan revealed mosaic attenuation and ground-glass opacities. Bronchoscopy was performed, and PCR testing confirmed the presence of Pneumocystis jirovecii. Other causes of hypercalcemia were ruled out, with PTH measured at 13.8 pg/mL (normal range 15–65 pg/mL), albumin at 3.71 g/dL, 1.25-dihydroxy vitamin D3 at 96 ng/dL (normal range 26–95 ng/dL), and 25-hydroxy vitamin D at 32.5 ng/mL (normal range 20–40 ng/mL). A PET-CT scan demonstrated no pathological FDG uptake, with the exception of findings suggestive of a pulmonary infection. Following treatment with trimethoprim-sulfamethoxazole and denosumab, the patient’s hypercalcemia and infection resolved.

Conclusions

 Although rare, PJP can present with hypercalcemia and kidney injury in allogeneic stem cell transplant recipients. Early diagnosis and treatment can improve both PJP and hypercalcemia.
Literature
1.
go back to reference Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis Jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–404.CrossRefPubMed Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis Jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–404.CrossRefPubMed
2.
go back to reference Bateman M, Oladele R, Kolls JK. Diagnosing pneumocystis jirovecii pneumonia: a review of current methods and novel approaches. Med Mycol. 2020;58(8):1015–28.CrossRefPubMedPubMedCentral Bateman M, Oladele R, Kolls JK. Diagnosing pneumocystis jirovecii pneumonia: a review of current methods and novel approaches. Med Mycol. 2020;58(8):1015–28.CrossRefPubMedPubMedCentral
3.
go back to reference Cordonnier C, Cesaro S, Maschmeyer G, et al. Pneumocystis Jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2379–85.CrossRefPubMed Cordonnier C, Cesaro S, Maschmeyer G, et al. Pneumocystis Jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2379–85.CrossRefPubMed
4.
go back to reference Kofteridis DP, Valachis A, Velegraki M, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis Jirovecii pneumonia in HIV-negative patients. J Infect Chemother. 2014;20(7):412–6.CrossRefPubMed Kofteridis DP, Valachis A, Velegraki M, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis Jirovecii pneumonia in HIV-negative patients. J Infect Chemother. 2014;20(7):412–6.CrossRefPubMed
5.
go back to reference Williams KM, Ahn KW, Chen M, et al. The incidence, mortality and timing of Pneumocystis Jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transpl. 2016;51(4):573–80.CrossRef Williams KM, Ahn KW, Chen M, et al. The incidence, mortality and timing of Pneumocystis Jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transpl. 2016;51(4):573–80.CrossRef
6.
go back to reference Kato H, Samukawa S, Takahashi H, Nakajima H. Diagnosis and treatment of Pneumocystis Jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole. J Infect Chemother. 2019;25(11):920–4.CrossRefPubMed Kato H, Samukawa S, Takahashi H, Nakajima H. Diagnosis and treatment of Pneumocystis Jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole. J Infect Chemother. 2019;25(11):920–4.CrossRefPubMed
7.
go back to reference Salzer HJF, Schäfer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-Infected and Non-HIV-Infected immunocompromised patients with Pneumocystis Jirovecii Pneumonia. Respiration. 2018;96(1):52–65.CrossRefPubMed Salzer HJF, Schäfer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-Infected and Non-HIV-Infected immunocompromised patients with Pneumocystis Jirovecii Pneumonia. Respiration. 2018;96(1):52–65.CrossRefPubMed
8.
go back to reference McKinnell JA, Cannella AP, Kunz DF, et al. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis. 2012;14(5):510–8.CrossRefPubMedPubMedCentral McKinnell JA, Cannella AP, Kunz DF, et al. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis. 2012;14(5):510–8.CrossRefPubMedPubMedCentral
9.
go back to reference Hamroun A, Lenain R, Bui Nguyen L, et al. Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients. Sci Rep. 2019;9(1):12508.CrossRefPubMedPubMedCentral Hamroun A, Lenain R, Bui Nguyen L, et al. Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients. Sci Rep. 2019;9(1):12508.CrossRefPubMedPubMedCentral
10.
go back to reference Yau AA, Farouk SS. Severe hypercalcemia preceding a diagnosis of Pneumocystis Jirovecii pneumonia in a liver transplant recipient. BMC Infect Dis. 2019;19(1):739.CrossRefPubMedPubMedCentral Yau AA, Farouk SS. Severe hypercalcemia preceding a diagnosis of Pneumocystis Jirovecii pneumonia in a liver transplant recipient. BMC Infect Dis. 2019;19(1):739.CrossRefPubMedPubMedCentral
11.
go back to reference Mascia G, Argiolas D, Carta E, Michittu MB, P GB. Acute kidney Injury secondary to Hypercalcemia in a kidney transplant patient with Pneumocystis Jirovecii Pneumonia: a Case Report. Transpl Proc. 2019;51(1):220–2. Mascia G, Argiolas D, Carta E, Michittu MB, P GB. Acute kidney Injury secondary to Hypercalcemia in a kidney transplant patient with Pneumocystis Jirovecii Pneumonia: a Case Report. Transpl Proc. 2019;51(1):220–2.
12.
go back to reference Chatzikyrkou C, Clajus C, Haubitz M, Hafer C. Hypercalcemia and pneumocystis pneumonia after kidney transplantation: report of an exceptional case and literature review. Transpl Infect Dis. 2011;13(5):496–500.CrossRefPubMed Chatzikyrkou C, Clajus C, Haubitz M, Hafer C. Hypercalcemia and pneumocystis pneumonia after kidney transplantation: report of an exceptional case and literature review. Transpl Infect Dis. 2011;13(5):496–500.CrossRefPubMed
13.
go back to reference Ramalho J, Bacelar Marques ID, Aguirre AR, Pierrotti LC, de Paula FJ, Nahas WC, et al. Pneumocystis Jirovecii pneumonia with an atypical granulomatous response after kidney transplantation. Transpl Infect Dis. 2014;16(2):315–9.CrossRefPubMed Ramalho J, Bacelar Marques ID, Aguirre AR, Pierrotti LC, de Paula FJ, Nahas WC, et al. Pneumocystis Jirovecii pneumonia with an atypical granulomatous response after kidney transplantation. Transpl Infect Dis. 2014;16(2):315–9.CrossRefPubMed
14.
go back to reference Hajji K, Dalle F, Harzallah A, Tanter Y, Rifle G, Mousson C. Vitamin D metabolite-mediated hypercalcemia with suppressed parathormone concentration in Pneumocystis Jirovecii pneumonia after kidney transplantation. Transpl Proc. 2009;41(8):3320–2.CrossRef Hajji K, Dalle F, Harzallah A, Tanter Y, Rifle G, Mousson C. Vitamin D metabolite-mediated hypercalcemia with suppressed parathormone concentration in Pneumocystis Jirovecii pneumonia after kidney transplantation. Transpl Proc. 2009;41(8):3320–2.CrossRef
15.
go back to reference Chen WC, Chang SC, Wu TH, Yang WC, Tarng DC. Hypercalcemia in a renal transplant recipient suffering with pneumocystis carinii pneumonia. Am J Kidney Dis. 2002;39(2):E8.CrossRefPubMed Chen WC, Chang SC, Wu TH, Yang WC, Tarng DC. Hypercalcemia in a renal transplant recipient suffering with pneumocystis carinii pneumonia. Am J Kidney Dis. 2002;39(2):E8.CrossRefPubMed
16.
go back to reference Bency R, Roger SD, Elder GJ. Hypercalcaemia as a prodromal feature of indolent pneumocystis jivorecii after renal transplantation. Nephrol Dial Transpl. 2011;26(5):1740–2.CrossRef Bency R, Roger SD, Elder GJ. Hypercalcaemia as a prodromal feature of indolent pneumocystis jivorecii after renal transplantation. Nephrol Dial Transpl. 2011;26(5):1740–2.CrossRef
17.
go back to reference Beale F, Gkiourtzis N, Koneru S, O’Brien C, Lalayiannis AD. Denosumab in a pediatric kidney transplant recipient with late, resistant hypercalcemia secondary to Pneumocystis Jirovecii pneumonia. Pediatr Nephrol. 2024;39(8):2355–8.CrossRefPubMed Beale F, Gkiourtzis N, Koneru S, O’Brien C, Lalayiannis AD. Denosumab in a pediatric kidney transplant recipient with late, resistant hypercalcemia secondary to Pneumocystis Jirovecii pneumonia. Pediatr Nephrol. 2024;39(8):2355–8.CrossRefPubMed
18.
go back to reference Hong L, Witton LD, Jolly EC. Pneumocystis Jirovecii pneumonia presenting with severe, refractory hypercalcaemia in an immunosuppressed renal transplant patient: review of the literature and novel biochemical insights. Clin Med (Lond). 2024;24(1):100011.CrossRefPubMed Hong L, Witton LD, Jolly EC. Pneumocystis Jirovecii pneumonia presenting with severe, refractory hypercalcaemia in an immunosuppressed renal transplant patient: review of the literature and novel biochemical insights. Clin Med (Lond). 2024;24(1):100011.CrossRefPubMed
Metadata
Title
Atypical presentation of PJP: hypercalcemia and kidney injury in an allogeneic stem cell transplant recipient
Authors
Yunus Can Özalp
Hajrij Shehabie
Mehmet Günhan Tekin
Süreyya Yiğit Kaya
Hüseyin Saffet Beköz
Senem Maral
Ömür Gökmen Sevindik
Leylagül Kaynar
Publication date
01-12-2024

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar
SPONSORED

Targeting COPD with type 2 inflammation: emerging biologic landscape

  • Webinar | 03-12-2024 | 19:00 (CET)

Join us for an insightful session tailored for pulmonologists and healthcaree professionals eager to enhance their understanding of COPD and the latest advances in biologic therapies. 

On-demand version coming soon

Sponsored by:
  • Sanofi
Developed by: Springer Healthcare
Learn more

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases